Precigen Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
$0.22next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Updates | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
PAPZIMEOS Net Product Revenue Quarterly21.6MTarget: Continued sequential growth in Q2 2026 and beyond
PAPZIMEOS Patient Hub Enrollment Quarterly400.0Target: Expansion of patient base across US medical centers and community settings
Cash, Cash Equivalents, and Investments Quarterly56.7MTarget: Sufficient liquidity to reach cash flow break-even by end of 2026
Watch Items
- EMA Marketing Authorization Application (MAA) for PAPZIMEOSTrigger: Validation completed in November 2025; under active reviewAction: Monitor regulatory feedback and potential approval timeline in late 2026 or early 2027
- Clinical development of PRGN-2009 in HPV-associated cancersTrigger: Ongoing Phase 2 trials under CRADA with NCI and in combination with pembrolizumabAction: Track clinical data readouts and planned AdenoVerse pipeline update by end of year 2026
- Competitive landscape from Inovio's INO-3107Trigger: Inovio filing for accelerated approval in RRPAction: Assess market share impact and commercial differentiation strategies
Research as of 20 Jun 2026